Risk factor profiles and clinical outcomes for children and adults with pneumococcal infections in Singapore: A need to expand vaccination policy?


Autoři: Rosario Martinez-Vega aff001;  Elita Jauneikaite aff002;  Koh Cheng Thoon aff004;  Hui Ying Chua aff001;  Amanda Huishi Chua aff001;  Wei Xin Khong aff001;  Ban Hock Tan aff006;  Jenny Low Guek Hong aff006;  Indumathi Venkatachalam aff006;  Paul Anantharajah Tambyah aff007;  Martin L. Hibberd aff002;  Stuart C. Clarke aff003;  Oon Tek Ng aff001
Působiště autorů: Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore aff001;  Infectious Diseases, Genome Institute of Singapore, Singapore, Singapore aff002;  Faculty of Medicine and Institute of Life Sciences, University of Southampton, Southampton, United Kingdom aff003;  Infectious Disease Service, Department of Paediatrics, KK Women’s and Children’s Hospital, Singapore, Singapore aff004;  Duke-NUS Graduate Medical School, Singapore, Singapore aff005;  Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore aff006;  Division of Infectious Diseases, National University of Singapore, Singapore, Singapore aff007;  National Centre for Infectious Diseases (NCID), Singapore, Singapore aff008;  Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore aff009
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0220951

Souhrn

Invasive pneumococcal infection is a major cause of morbidity and mortality worldwide despite the availability of pneumococcal vaccines. The aim of this study was to re-evaluate the clinical syndromes, prognostic factors and outcomes for pneumococcal disease in adults and children in Singapore during the period before and after the introduction of the pneumococcal vaccine. We retrospectively analyzed a large cohort of patients admitted to the four main public hospitals in Singapore with S. pneumoniae infection between 1997 and 2013. A total of 889 (64% of all isolates identified in the clinical laboratories) cases were included in the analysis; 561 (63.1%) were adult (≥16 years) cases with a median age of 62 years and 328 (36.9%) were paediatric cases with a median age of 3 years. Bacteraemic pneumonia was the most common syndrome in both groups (69.3% vs. 44.2%), followed by primary bacteraemia without pneumonia (14.3% vs. 13.4%), meningitis (6.4% vs. 7.6%) and non-bacteraemic pneumonia (5.2% vs. 21%). The major serotypes in adults were 3, 4, 6B, 14, 19F and 23F whereas in children they were 14, 6B and 19F, accounting both for nearly half of pneumococcal disease cases. No particular serotype was associated with mortality or severity of the pneumococcal disease. Overall mortality rate was 18.5% in adults and 3% in children. Risk factors for mortality included acute cardiac events in adults, meningitis in children and critical illness and bilateral pulmonary infiltrates in both adults and children. Penicillin resistance was not associated with increased mortality. Our results agree with global reports that the course of pneumococcal disease and its clinical outcome were more severe in adults than in children. The main serotypes causing invasive disease were mostly covered by the vaccines in use. The high mortality rates reflect an urgent need to increase vaccination coverage in both adults and children to tackle this vaccine-preventable infection.

Klíčová slova:

Antibiotics – Death rates – Pneumococcus – Pneumonia – Singapore – Vaccination and immunization – Vaccines – Meningitis


Zdroje

1. Immunization, Vaccines and Biologicals Pneumococcal disease [Internet]. 2016 Jul pp. 1–2. http://www.who.int/immunization/topics/pneumococcal_disease/en/#

2. Gillespie SH, Balakrishnan I. Pathogenesis of pneumococcal infection. J Med Microbiol. Microbiology Society; 2000;49: 1057–1067. doi: 10.1099/0022-1317-49-12-1057 11129716

3. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25: 409–419. doi: 10.1128/CMR.00018-12 22763632

4. Jansen AGSC, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis. Oxford University Press; 2009;49: e23–9. doi: 10.1086/600045 19522653

5. Bogaert D, Hermans PWM, Adrian PV, Rümke HC, De Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine. 2004;22: 2209–2220. doi: 10.1016/j.vaccine.2003.11.038 15149779

6. Hyams C, Camberlein E, Cohen JM, Bax K, Brown JS. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun. 2010;78: 704–715. doi: 10.1128/IAI.00881-09 19948837

7. Jauneikaite E, Tocheva AS, Jefferies JMC, Gladstone RA, Faust SN, Christodoulides M, et al. Current methods for capsular typing of Streptococcus pneumoniae. J Microbiol Methods. 2015;113: 41–49. doi: 10.1016/j.mimet.2015.03.006 25819558

8. Health SMO. Epidemiological News Bulletin [Internet]. https://www.moh.gov.sg/content/dam/moh_web/Publications/Epidemiological%20News%20Bulletin/ENB%20Quarterly_Jul%202017%20Vol%2043%20No.3%20(Final).pdf

9. Eng P, Lim LH, Loo CM, Low JA, Tan C, Tan EK, et al. Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore. Int J Gen Med. Dove Press; 2014;7: 179–191. doi: 10.2147/IJGM.S54963 24729726

10. Singapore SOID. Clinical Practice Guidelines on Adult Vaccination in Singapore. 1st ed. Singapore:2016. [Internet]. URL:http://ams.edu.sg/view—pdf.aspx?file=media%5C3075_fi_366.pdf&ofile=Adult%2BVaccination%2BGuidelines_HR2+One+PDF.pdf

11. How CH, Phua See Chun P, Shafi F, Jakes RW. Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessment. BMC Public Health. BioMed Central; 2016;16: 923. doi: 10.1186/s12889-016-3597-5 27590503

12. Paterson DL, Ko WC, Gottberg von A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140: 26–32. doi: 10.7326/0003-4819-140-1-200401060-00008 14706969

13. CLSI. M100-S24: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. 2014 Jan pp. 1–230.

14. Navarro-Torné A, Dias JG, Hruba F, Lopalco PL, Pastore-Celentano L, Gauci AJA, et al. Risk factors for death from invasive pneumococcal disease, Europe, 2010. Emerging Infect Dis. 2015;21: 417–425. doi: 10.3201/eid2103.140634 25693604

15. Yu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. Oxford University Press; 2003;37: 230–237. doi: 10.1086/377534 12856216

16. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19: 716–723. doi: 10.1109/TAC.1974.1100705

17. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis. Oxford University Press; 2009;49: 205–212. doi: 10.1086/599827 19508165

18. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. Massachusetts Medical Society; 2009;360: 244–256. doi: 10.1056/NEJMoa0800836 19144940

19. Health SMO. Communicable Diseases Surveillance in Singapore 2012 [Internet]. https://www.moh.gov.sg/docs/librariesprovider5/resources-statistics/reports/childhood-immunisationf0f0fb82a2a143718a25f214f300a71d.pdf

20. Vestrheim DF, Steinbakk M, Aaberge IS, Caugant DA. Postvaccination increase in serotype 19A pneumococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 complex. Clin Vaccine Immunol. 2012;19: 443–445. doi: 10.1128/CVI.05563-11 22237889

21. Andam CP, Mitchell PK, Callendrello A, Chang Q, Corander J, Chaguza C, et al. Genomic Epidemiology of Penicillin-Nonsusceptible Pneumococci with Nonvaccine Serotypes Causing Invasive Disease in the United States. Richter SS, editor. J Clin Microbiol. 2017;55: 1104–1115. doi: 10.1128/JCM.02453-16 28100596

22. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study). Antimicrob Agents Chemother. 2004;48: 2101–2107. doi: 10.1128/AAC.48.6.2101-2107.2004 15155207

23. Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis. Elsevier; 2006;56: 427–436. doi: 10.1016/j.diagmicrobio.2006.07.003 16938419

24. Vasoo S, Singh K, Hsu LY, Chiew YF, Chow C, Lin RTP, et al. Increasing antibiotic resistance in Streptococcus pneumoniae colonizing children attending day-care centres in Singapore. Respirology. Blackwell Publishing Asia; 2011;16: 1241–1248. doi: 10.1111/j.1440-1843.2011.02036.x 21848708

25. Chong CY, Koh-Cheng T, Yee-Hui M, Nancy TW-S. Invasive pneumococcal disease in Singapore children. Vaccine. 2008;26: 3427–3431. doi: 10.1016/j.vaccine.2008.04.035 18499309

26. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppälä H, Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006;50: 3646–3650. doi: 10.1128/AAC.00234-06 16940064

27. Dagan R, Barkai G, Leibovitz E, Dreifuss E, Greenberg D. Will reduction of antibiotic use reduce antibiotic resistance?: The pneumococcus paradigm. Pediatr Infect Dis J. 2006;25: 981–986. doi: 10.1097/01.inf.0000239266.20642.26 17006311

28. Ekdahl K, Ahlinder I, Hansson HB, Melander E, Mölstad S, Söderström M, et al. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis. 1997;25: 1113–1117. doi: 10.1086/516103 9402367

29. Lynch JP, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med. © Thieme Medical Publishers; 2009;30: 210–238. doi: 10.1055/s-0029-1202939 19296420

30. Thoon KC, Chong CY, Tee NWS. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010. Int J Infect Dis. Elsevier; 2012;16: e209–15. doi: 10.1016/j.ijid.2011.11.014 22281191

31. Imran MN, Leng PH, Yang S, Kurup A, Eng P. Early predictors of mortality in pneumococcal bacteraemia. Ann Acad Med Singap. 2005;34: 426–431. 16123815

32. Alanee SRJ, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis. Oxford University Press; 2007;45: 46–51. doi: 10.1086/518538 17554699

33. Low S, Chan FLF, Cutter J, Ma S, Goh KT, Chew SK. A national study of the epidemiology of pneumococcal disease among hospitalised patients in Singapore: 1995 to 2004. Singapore Med J. 2007;48: 824–829. 17728963

34. Verhaegen J, Flamaing J, De Backer W, Delaere B, Van Herck K, Surmont F, et al. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011. Euro Surveill. 2014;19: 14–22.

35. Martens P, Worm SW, Lundgren B, Konradsen HB, Benfield T. Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infectious Diseases. BioMed Central; 2004;4: 21. doi: 10.1186/1471-2334-4-21 15228629

36. Klemets P, Lyytikäinen O, Ruutu P, Ollgren J, Nuorti JP. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infectious Diseases. BioMed Central; 2008;8: 96. doi: 10.1186/1471-2334-8-96 18647385


Článek vyšel v časopise

PLOS One


2019 Číslo 10